ImmunoCellular seeks next level leader after CEO resignation 'mess'
This article was originally published in Scrip
ImmunoCellular Therapeutics founder, chief scientific officer and chairman John Yu told Scrip that the Los Angeles-based cancer vaccine developer is "looking for a leader to take the company to the next level" since president and CEO Manish Singh resigned "to pursue other opportunities."
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.